Cleveland Clinic settles with DOJ in gender-affirming care investigation

Cleveland Clinic Settles With DOJ Over Gender-Affirming Care Allegations

Cleveland Clinic settles with DOJ in gender - The Cleveland Clinic has reached a settlement with the U.S. Department of Justice (DOJ) in a case related to gender-affirming care for minors, agreeing to allocate $2 million toward detransition services for individuals who undergo such treatments as children. This marks the second major healthcare system to resolve claims under the Trump administration’s scrutiny of transgender care practices, following a similar agreement with Texas Children’s Hospital. The settlement, announced on Friday, aims to address accusations that the clinic improperly billed insurance for procedures intended to align a person’s physical characteristics with their gender identity.

Details of the Settlement Agreement

Under the terms of the deal, the Cleveland Clinic will provide detransition care to all patients, irrespective of their financial status. This includes access to medical services for hormonal balance, surgical revisions, and fertility restoration, alongside psychological support and insurance coordination. The clinic is also required to launch a dedicated platform for these services, featuring a website, a phone number, and a care coordinator. Additionally, it will conduct outreach programs targeting three organizations that offer non-medical support to those seeking detransition.

The DOJ emphasized that the settlement is a step toward ensuring that individuals who receive gender-affirming care as minors have access to corrective measures if they choose to detransition. In a statement, the agency described its role as providing “essential care for individuals experiencing adverse effects from medical interventions administered during childhood.” This commitment reflects the DOJ’s stance on addressing perceived harms of early gender-affirming treatments, particularly puberty blockers and cross-sex hormones.

Advocates Criticize the Settlement

Transgender rights advocates have condemned the agreement, calling it a concession to anti-trans ideology. Dara Adkison, executive director of TransOhio, argued that the clinic’s actions undermine medical integrity. “Cleveland Clinic, once a highly respected medical institution, continues to prioritize compliance with political agendas over scientific evidence,” Adkison stated in a

“The Clinic’s decision to fund detransition services signals a shift away from supporting transgender youth, who have shown remarkable resilience in navigating gender transitions.”

She further noted that detransition care is an inherent part of gender-affirming treatment and that the settlement perpetuates a narrative of “bigoted performative farce” by highlighting its importance while ignoring the broader context of care for transgender individuals.

Other supporters of the settlement have framed it as a necessary measure to protect children from irreversible medical decisions. They argue that detransition services are essential for individuals who may later regret their transition, emphasizing the need for a comprehensive approach to care. However, critics contend that the settlement pressures families into making choices based on political rhetoric rather than medical necessity.

Comparison to Texas Children’s Hospital Settlement

While the Cleveland Clinic’s settlement is significantly smaller than the $10 million agreement with Texas Children’s Hospital, both cases highlight the DOJ’s focus on gender-affirming care for minors. The Texas deal established the nation’s first “detransition clinic,” a dedicated facility for reversing transgender procedures. The Cleveland Clinic’s $300,000 contribution to the U.S. and Ohio, though less costly, includes a 20-year pledge to refrain from offering gender-affirming care to children. This commitment aligns with state laws in Ohio, which already prohibit minors from receiving such treatments, creating a dual layer of regulation.

The DOJ’s allegations centered on the use of specific diagnosis codes to justify insurance claims for gender-affirming procedures. By substituting codes for unspecified endocrine disorders with those that more clearly indicate the rationale for treatment, the clinic allegedly secured coverage for interventions that some argue are not medically necessary. This practice has been a focal point of the administration’s efforts to challenge the validity of gender-affirming care, particularly in cases involving minors.

Broader Implications for Transgender Care

The settlement raises questions about the future of gender-affirming care in the U.S. and its alignment with federal policy. While the Cleveland Clinic’s agreement is a modest financial commitment, it underscores the growing pressure on healthcare providers to conform to anti-trans narratives. The DOJ’s actions suggest a continued emphasis on detransition services as a critical component of care, even as the clinic retains its status as a leading medical institution.

For families of transgender youth, the settlement may offer a sense of reassurance that their children’s care is being closely monitored. However, advocates warn that it could also deter parents from pursuing gender-affirming treatments, fearing legal consequences or the need to cover detransition costs. The inclusion of psychological support and insurance coordination in the agreement reflects an attempt to balance the needs of both transgender individuals and those who choose to detransition, though critics argue these services are being used to justify a broader ideological agenda.

State Laws and Federal Enforcement

Ohio’s existing ban on gender-affirming care for minors provides a legal framework that complements the DOJ’s settlement. This state law, enacted to limit the availability of such treatments, has been a point of contention for advocates who view it as a barrier to transgender youth accessing care. The Cleveland Clinic’s 20-year pledge, while voluntary, aligns with this state policy, reinforcing a consistent approach to regulating gender-affirming treatments across both state and federal levels.

Despite the settlement, the clinic has not fully withdrawn from providing gender-affirming care. It will continue to offer services to minors but with a commitment to detransition options. This dual strategy may appeal to parents seeking a middle ground between full support for transgender care and the possibility of reversal. The DOJ’s statement, however, asserts that its enforcement of federal law is a means to “protect America’s children” from what it deems as harmful interventions, framing the settlement as a proactive measure to ensure accountability.

As the Cleveland Clinic moves forward with its detransition services, the debate over gender-affirming care is likely to intensify. The settlement sets a precedent for how healthcare systems might navigate the intersection of medical ethics, political priorities, and legal obligations. For now, the agreement represents a compromise that balances the interests of various stakeholders, but its long-term impact on transgender healthcare remains a subject of discussion among experts and activists alike.

The Hill has sought comment from Cleveland Clinic on its stance and the broader implications of the settlement. In response, the clinic may emphasize its dedication to providing care that respects both transgender identities and the potential for detransition, positioning itself as a flexible and patient-centered institution. As the DOJ continues its investigations, the case serves as a microcosm of the larger ideological and legal battles shaping the landscape of gender-affirming care in the United States.